CIK 0001861123 · <br>Emerging growth company
Eikon Therapeutics, Inc.
Sign in to watch- Ticker
- EIKN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842807586
- Phone
- 341-777-0566
- Business address
- 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
- Open-market buys, last 90 days
- $1,031,045
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$1,031,045. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-06 | Column Group IV GP, LP 10% owner | Purchase | +630,881 | $18.00 | $11.4M | 1,319,164 |
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series A Preferred Stock | −9,670,000 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series A Preferred Stock | −330,000 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series A-1 Preferred Stock | −10,467,526 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series A-1 Preferred Stock | −357,216 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series C-1 Preferred Stock | −827,278 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series C-1 Preferred Stock | −28,229 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion · Series D Preferred Stock | −5,133,076 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion | +2,387,705 | 2,387,705 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion | +1,151,540 | 1,290,428 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion | +2,155,765 | 2,294,653 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series A Preferred Stock | −10,000,000 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series A-1 Preferred Stock | −7,807,026 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series A-1 Preferred Stock | −2,502,252 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series B Preferred Stock | −796,380 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series B Preferred Stock | −530,920 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series B-1 Preferred Stock | −5,289,322 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series B-1 Preferred Stock | −3,526,215 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series C Preferred Stock | −303,360 | 0 | ||
| 2026-02-06 | Wolfe Josh Director | Conversion · Series C-1 Preferred Stock | −1,450,614 | 0 |
Page 2 of 5 · 88 trades